Weijiao Du

Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

Jinpu Yu, Weijiao Du, Yan Fang et al. · The Journal of Immunology · 2013 · 604 citations

Medicine, Immunology, Oncology +17

A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer

Li Zhou, Yanjuan Xiong, Yang Wang et al. · Clinical Lung Cancer · 2022 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial

Qiuzhong Pan, Jingjing Zhao, Liang Liu et al. · Signal Transduction and Targeted Therapy · 2024 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

Autologous cytokine‐induced killer (<scp>CIK</scp>) cells enhance the clinical response to <scp>PD‐1</scp> blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study

Ying Han, Di Mu, Ting Liu et al. · Thoracic Cancer · 2020 · 23 citations · Full text

Life Sciences, Immunology, Oncology +17

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification

Xiaomeng Wang, Jie Cao, Weijiao Du et al. · Clinical Case Reports · 2021 · 10 citations · Full text

Medicine, Molecular Genetics, Oncology +17